{"id":"W4284988981","doi":"10.1002/mds.29133","title":"The Interaction between <scp><i>HLA‐DRB1</i></scp> and Smoking in Parkinson's Disease Revisited","year":2022,"lang":"en","type":"article","venue":"Movement Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; Occupational Cancer Research Centre; University of Toronto","funders":"National Institute of Environmental Health Sciences; National Institute on Aging; Faculty of Medicine and Health, University of Sydney; Instituto de Salud Carlos III; Medical Research Council; Pfizer Japan; Novartis Pharma; Parkinsonfonden; National Institutes of Health; Parkinson Vereniging; Ono Pharmaceutical; FP Pharmaceutical Corporation; Mitsubishi Tanabe Pharma Corporation; Skånes universitetssjukhus; Association France Parkinson; Medical Research Council Canada; Lunds Universitet; Norges Forskningsråd; Department of Forestry and Natural Resources, Purdue University; European Commission; Fondazione Pierfranco e Luisa Mariani; Ministero della Salute; Helse Sør-Øst RHF; Sanofi K.K.; Eesti Teadusagentuur; Daiichi Sankyo Europe; Karolinska Institutet; ZonMw; Biogen; Agence Nationale de la Recherche; Sanofi; Fondation de France; Idorsia Pharmaceuticals; Université Paris-Saclay; Department of Science and Technology, Ministry of Science and Technology, India; Fondation Roger de Spoelberch; South African Medical Research Council; Hersenstichting; Radboud Universiteit; National Research Foundation; University College London; Verily Life Sciences; Universiteit Stellenbosch; Parkinson's UK; Bundesministerium für Bildung und Forschung; Nasjonalforeningen for Folkehelsen; Boehringer Ingelheim Japan; Fondazione Cariplo; Kissei; Alexion Pharmaceuticals; EVER Neuro Pharma; Nihon Medi-Physics; Université du Luxembourg; Pfizer; EU Joint Programme – Neurodegenerative Disease Research; Teva Pharmaceutical Industries; Japan Society for the Promotion of Science; Astellas Pharma; Horizon 2020 Framework Programme; Vetenskapsrådet; Eisai; Boston Scientific Japan; Deutsche Forschungsgemeinschaft; Japan Agency for Medical Research and Development; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas; Ministerio de Ciencia e Innovación; UCB Pharma; Demensfonden; Meiji Seika Pharma; Hjärnfonden; U.S. Department of Defense; Mylan; Boston Scientific Corporation; Michael J. Fox Foundation for Parkinson's Research; Multiple Sclerosis Society of Western Australia; Consortium canadien en neurodégénérescence associée au vieillissement; Hellenic Foundation for Research and Innovation; General Secretariat for Research and Technology; Multiple System Atrophy Coalition; U.S. Department of Health and Human Services","keywords":"Odds ratio; Parkinson's disease; Single-nucleotide polymorphism; Confidence interval; Disease; Psychology; Mendelian randomization; Human leukocyte antigen; Genetics; Medicine; Internal medicine; Biology; Genotype; Gene; Antigen","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002982928,0.0001972628,0.0002139,0.0001474351,0.0005024294,0.00005479736,0.0001045378,0.00002484017,0.00005926315],"category_scores_gemma":[0.00008624594,0.0001621646,0.00009444809,0.0002835667,0.00004110444,0.00009349084,0.0001814494,0.0002317006,0.000004938579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002664265,"about_ca_system_score_gemma":0.00004813024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000164051,"about_ca_topic_score_gemma":0.00004150447,"domain_scores_codex":[0.9984502,0.0001218586,0.0002539499,0.0003934933,0.0004247413,0.0003557252],"domain_scores_gemma":[0.9992075,0.0001604238,0.0001122368,0.0002943996,0.00001658968,0.0002088514],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001201901,0.0003769597,0.9644024,0.00004929282,0.0001914153,0.00006342988,0.0002697786,0.00004356006,0.00004716688,0.0005754955,0.002640821,0.03121944],"study_design_scores_gemma":[0.002402178,0.0001965256,0.6790513,0.0000528776,0.0001886008,3.863435e-7,0.002097717,0.0005036813,0.00004882826,0.01047132,0.3049081,0.00007847796],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923833,0.002827945,0.00008705158,0.002475791,0.0001626884,0.0008131338,0.00006139525,0.00005703359,0.001131675],"genre_scores_gemma":[0.9957474,0.0009813891,0.00002491356,0.002222686,0.00004406675,0.0003595962,0.0001505686,0.00003022359,0.0004391015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3022673,"threshold_uncertainty_score":0.6612881,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0136195384631499,"score_gpt":0.2586110272850121,"score_spread":0.2449914888218622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}